Open Government Portal
Open Data Search has recently undergone significant changes. The search page has moved to search.open.canada.ca/opendata. Please update existing bookmarks accordingly.
Found 10 records similar to Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications
Drugs and vaccines that have been authorized by Health Canada for use in relation to the COVID-19 pandemic are listed in this document.
Drugs and vaccines that have been authorized by Health Canada for use in relation to the COVID-19 pandemic are listed here.
The tables below list the COVID-19-related clinical trials which have been authorized by Health Canada through the Food and Drug Regulations or the Interim order No. 2 for clinical trials for medical devices and drugs related to COVID-19.
How Health Canada is addressing clinical trials of drugs and vaccines, its expedited review process and the Special Access Program to find therapies to prevent or treat COVID-19.
COVID-19 vaccine ingredients in the Pfizer-BioNTech, Moderna and AstraZeneca vaccines.
The list below includes all applications received by Health Canada for drugs and vaccines used for the COVID-19 pandemic. This list includes applications received under the interim order and those received under the Food and Drug Regulations. The current status of each application is also noted.
The tables below list the COVID-19-related clinical trials which have been authorized by Health Canada through the Food and Drug Regulations or the Interim order No. 2 for clinical trials for medical devices and drugs related to COVID-19.
We are collaborating with other national regulatory authorities to align the requirements for evaluating, authorizing and post-market surveillance of variant COVID-19 vaccines as much as possible.
Variant strains of SARS-CoV-2 are emerging that may affect the level of protection provided by currently authorized COVID-19 vaccines. As a result, manufacturers are adapting authorized COVID-19 vaccines to provide protection against infection and disease caused by virus variants.
This document provides guidance to vaccine manufacturers seeking authorization for their vaccine that targets the SARS-CoV-2 virus. This guidance applies to applications under the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19.